JP2008523090A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008523090A5 JP2008523090A5 JP2007545655A JP2007545655A JP2008523090A5 JP 2008523090 A5 JP2008523090 A5 JP 2008523090A5 JP 2007545655 A JP2007545655 A JP 2007545655A JP 2007545655 A JP2007545655 A JP 2007545655A JP 2008523090 A5 JP2008523090 A5 JP 2008523090A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- drug
- pphn
- pao
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 88
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 claims 39
- 239000003814 drug Substances 0.000 claims 30
- 229940079593 drug Drugs 0.000 claims 26
- 239000013078 crystal Substances 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 18
- 239000012453 solvate Substances 0.000 claims 18
- 239000002243 precursor Substances 0.000 claims 14
- 229910052760 oxygen Inorganic materials 0.000 claims 13
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 10
- 239000001301 oxygen Substances 0.000 claims 10
- FEMXZDUTFRTWPE-DZSWIPIPSA-N L-erythro-7,8-dihydrobiopterin Chemical compound N1C(N)=NC(=O)C2=C1NCC([C@@H](O)[C@@H](O)C)=N2 FEMXZDUTFRTWPE-DZSWIPIPSA-N 0.000 claims 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims 6
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 229960000304 folic acid Drugs 0.000 claims 6
- 235000019152 folic acid Nutrition 0.000 claims 6
- 239000011724 folic acid Substances 0.000 claims 6
- -1 nitropreside Chemical compound 0.000 claims 6
- 229940124549 vasodilator Drugs 0.000 claims 6
- 239000003071 vasodilator agent Substances 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 4
- 230000036266 weeks of gestation Effects 0.000 claims 4
- QYNUQALWYRSVHF-OLZOCXBDSA-N (6R)-5,10-methylenetetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C1)N)N1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QYNUQALWYRSVHF-OLZOCXBDSA-N 0.000 claims 3
- MSTNYGQPCMXVAQ-RYUDHWBXSA-N (6S)-5,6,7,8-tetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-RYUDHWBXSA-N 0.000 claims 3
- VVIAGPKUTFNRDU-STQMWFEESA-N (6S)-5-formyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C=O)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-STQMWFEESA-N 0.000 claims 3
- ZNOVTXRBGFNYRX-STQMWFEESA-N (6S)-5-methyltetrahydrofolic acid Chemical compound C([C@@H]1N(C=2C(=O)N=C(N)NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-STQMWFEESA-N 0.000 claims 3
- AUFGTPPARQZWDO-YPMHNXCESA-N 10-formyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)N(C=O)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 AUFGTPPARQZWDO-YPMHNXCESA-N 0.000 claims 3
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 claims 3
- YCWUVLPMLLBDCU-STQMWFEESA-N 5-formimidoyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C=N)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YCWUVLPMLLBDCU-STQMWFEESA-N 0.000 claims 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 3
- VPVOXUSPXFPWBN-UHFFFAOYSA-N L-sepiapterin Natural products N1=C(N)NC(=O)C2=C1NCC(C(=O)C(O)C)=N2 VPVOXUSPXFPWBN-UHFFFAOYSA-N 0.000 claims 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 3
- 229960001123 epoprostenol Drugs 0.000 claims 3
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 claims 3
- 210000004072 lung Anatomy 0.000 claims 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims 3
- VPVOXUSPXFPWBN-VKHMYHEASA-N sepiapterin Chemical compound N1C(N)=NC(=O)C2=C1NCC(C(=O)[C@@H](O)C)=N2 VPVOXUSPXFPWBN-VKHMYHEASA-N 0.000 claims 3
- 229940126478 sepiapterin Drugs 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 229910002092 carbon dioxide Inorganic materials 0.000 claims 2
- 239000001569 carbon dioxide Substances 0.000 claims 2
- 238000002648 combination therapy Methods 0.000 claims 2
- 238000002592 echocardiography Methods 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 230000002028 premature Effects 0.000 claims 2
- 229960004617 sapropterin Drugs 0.000 claims 2
- 230000002861 ventricular Effects 0.000 claims 2
- 208000002330 Congenital Heart Defects Diseases 0.000 claims 1
- 208000028831 congenital heart disease Diseases 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 208000004594 persistent fetal circulation syndrome Diseases 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 230000031877 prophase Effects 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63414704P | 2004-12-08 | 2004-12-08 | |
| PCT/US2005/044587 WO2006063215A2 (en) | 2004-12-08 | 2005-12-08 | Methods and compositions for the treatment of pulmonary hypertension of the newborn |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008523090A JP2008523090A (ja) | 2008-07-03 |
| JP2008523090A5 true JP2008523090A5 (enExample) | 2008-11-27 |
Family
ID=36578615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007545655A Withdrawn JP2008523090A (ja) | 2004-12-08 | 2005-12-08 | 新生児肺高血圧症の治療のための方法および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20100130500A1 (enExample) |
| EP (1) | EP1819340A2 (enExample) |
| JP (1) | JP2008523090A (enExample) |
| AU (1) | AU2005313940A1 (enExample) |
| CA (1) | CA2588994A1 (enExample) |
| WO (1) | WO2006063215A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2436379A1 (en) | 2004-11-17 | 2012-04-04 | BioMarin Pharmaceutical Inc. | Stable tablet formulation |
| JP4864400B2 (ja) * | 2005-09-22 | 2012-02-01 | トヨタホーム株式会社 | ラック |
| WO2007067570A1 (en) * | 2005-12-05 | 2007-06-14 | Biomarin Pharmaceutical Inc. | Methods and compositions for the treatment of disease |
| PL2076501T3 (pl) * | 2006-09-25 | 2016-06-30 | Ptc Therapeutics Inc | Postacie krystaliczne kwasu 3-[5-(2-fluorofenylo)[1,2,4]oksadiazol-3-ilo]-benzoesowego |
| RU2470642C2 (ru) | 2008-01-03 | 2012-12-27 | Байомарин Фармасьютикл Инк. | Аналоги птерина для лечения состояния, чувствительного к вн4 |
| JP2011010865A (ja) | 2009-06-30 | 2011-01-20 | Ikaria Holdings Inc | 肺高血圧の臨床的または超音波心臓検査上の証拠を伴う低酸素性呼吸器不全に罹った満期産およびほぼ満期産の新生児を治療する方法 |
| US8641613B2 (en) | 2011-03-10 | 2014-02-04 | Medicalcue, Inc. | Umbilical probe system |
| US8641614B2 (en) * | 2011-03-10 | 2014-02-04 | Medicalcue, Inc. | Umbilical probe measurement systems |
| US8727980B2 (en) | 2011-03-10 | 2014-05-20 | Medicalcue, Inc. | Umbilical probe system |
| JP2014527025A (ja) * | 2011-05-27 | 2014-10-09 | ゲノ エルエルシー | 吸入用一酸化窒素を用いて血管反応性を決定する方法 |
| US9216178B2 (en) | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
| US20140373836A1 (en) | 2013-06-25 | 2014-12-25 | Ino Therapeutics Llc | Methods of Reducing the Risk of Mortality Associated With a Medical Treatment |
| IL266955B2 (en) | 2016-11-29 | 2023-09-01 | Ptc Therapeutics Mp Inc | Polymorphs of spiafatrin and its salts |
| WO2018102314A1 (en) | 2016-11-29 | 2018-06-07 | Censa Pharmaceuticals Inc. | Polymorphic form of sepiapterin |
| WO2019046849A1 (en) | 2017-09-01 | 2019-03-07 | Censa Pharmaceuticals Inc. | PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF |
| SMT202400430T1 (it) | 2018-05-30 | 2024-11-15 | Ptc Therapeutics Mp Inc | Somministrazione di sepiapterina, senza alcun alimento, per uso in un metodo per incrementare l’esposizione plasmatica di sepiapterina |
| EP3801534A4 (en) | 2018-05-30 | 2022-03-16 | PTC Therapeutics MP, Inc. | COMPOSITIONS AND METHODS TO INCREASE TETRAHYDROBIOPTERIN PLASMA EXPOSURE |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2601215A (en) * | 1948-03-17 | 1952-06-17 | American Cyanamid Co | Process of preparing dihydropterins |
| US3505329A (en) * | 1968-02-06 | 1970-04-07 | Smithkline Corp | Process for the synthesis of biopterin |
| JPS5883691A (ja) * | 1981-11-13 | 1983-05-19 | Kanegafuchi Chem Ind Co Ltd | １′，２′−ジアシル−（６ｒ，ｓ）−５，６，７，８−テトラヒドロ−ｌ−ビオプテリンおよびその製法 |
| JPS5925323A (ja) * | 1982-03-03 | 1984-02-09 | 鐘淵化学工業株式会社 | プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤 |
| GB8318833D0 (en) * | 1983-07-12 | 1983-08-10 | Wellcome Found | Chemical compounds |
| ZA836957B (en) * | 1982-09-20 | 1985-04-24 | Wellcome Found | Neurologically active chemical compounds |
| US5196533A (en) * | 1983-04-11 | 1993-03-23 | South Alabama Medical Science Foundation, Usa | Cyclization of 5 amino-pyrimidines to quinoid 6,6 disubstituted dihydropteridines |
| US4587340A (en) * | 1983-09-19 | 1986-05-06 | Burroughs Wellcome Co. | Biopterin analogs |
| JPS60178887A (ja) * | 1984-02-23 | 1985-09-12 | Kanegafuchi Chem Ind Co Ltd | ５，６，７，８−テトラヒドロ−ｌ−ビオプテリンの製造法 |
| JPS60199889A (ja) * | 1984-03-24 | 1985-10-09 | Kanegafuchi Chem Ind Co Ltd | ５，６，７，８−テトラヒドロ−ｌ−エリスロ−ビオプテリンの硫酸塩およびその製法 |
| US4550109A (en) * | 1984-05-31 | 1985-10-29 | The Board Of Regents, The University Of Texas System | Lipoidal biopterin compounds |
| DE3437944A1 (de) * | 1984-10-17 | 1986-07-31 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Verwendung von pterinen zur steigerung der aktivitaet von lymphokinen und anderen blutfaktoren, sowie ein diagnostisches oder therapeutisches praeparat, das pterine in kombination mit lymphokinen enthaelt |
| US4713454A (en) * | 1985-01-28 | 1987-12-15 | Shiratori Pharmaceutical Co., Ltd. | Preparation process of (6R)-tetrahydro-L-biopterin |
| JPS61277618A (ja) * | 1985-06-04 | 1986-12-08 | Suntory Ltd | 自閉症治療剤 |
| EP0318926B1 (en) * | 1987-11-30 | 1995-05-03 | Kabushiki Kaisha Vitamin Kenkyusyo | Intermediates for synthesizing 5,6,7,8-tetrahydro-L-erythro-biopterin and its derivatives |
| JP2534423B2 (ja) * | 1991-12-26 | 1996-09-18 | コーネル・リサーチ・ファンデーション・インコーポレイテッド | 酸化窒素の過剰生産から生じる血管失調を阻止する阻害剤 |
| US5198547A (en) * | 1992-03-16 | 1993-03-30 | South Alabama Medical Science Foundation, Usa | Process for N5-formylating tetrahydropteridines |
| DE4308739C1 (de) * | 1993-03-19 | 1994-06-23 | Henning Berlin Gmbh | Pterinderivate, ihre Herstellung und ihre Verwendung |
| CH686369A5 (de) * | 1994-05-09 | 1996-03-15 | Eprova Ag | Stabile kristalline (6S)- und (6R)-Tetrahydrofolseure. |
| US5945452A (en) * | 1993-06-11 | 1999-08-31 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity |
| US5502050A (en) * | 1993-11-29 | 1996-03-26 | Cornell Research Foundation, Inc. | Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis |
| ES2177654T3 (es) * | 1994-08-05 | 2002-12-16 | Suntory Ltd | Remedio contra la degeneracion espinocerebelosa. |
| US20020076782A1 (en) * | 1996-07-05 | 2002-06-20 | John P.N. Rosazza | Purified nitric oxide synthase |
| US6720309B1 (en) * | 1996-07-17 | 2004-04-13 | Leuven Research And Development, V.Z.W. | Method of inducing vasodilation and treating pulmonary hypertension using adenoviral-mediated transfer of the nitric oxide synthase gene |
| GB9617990D0 (en) * | 1996-08-29 | 1996-10-09 | Scotia Holdings Plc | Treatment of pain |
| WO1998008516A1 (en) * | 1996-08-30 | 1998-03-05 | Suntory Limited | Preventives or remedies for diseases induced by hypofunction of nitric oxide synthase (nos) |
| CH693255A5 (de) * | 1997-06-13 | 2003-05-15 | Eprova Ag | Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels. |
| US5922713A (en) * | 1997-06-26 | 1999-07-13 | Werner; Ernst | Inhibition of nitric oxide synthase |
| JP4306825B2 (ja) * | 1998-02-27 | 2009-08-05 | アスビオファーマ株式会社 | インスリン抵抗性が関与する血管機能異常を伴う疾患の予防または治療剤 |
| US6200758B1 (en) * | 1999-02-19 | 2001-03-13 | New York State Office Of Mental Health | Phenylalanine hydroxylase gene variants, and amino acid and pterin homeostasis, in the definition, detection, treatment and prevention of psychotic, mood and personality disorders |
| US6521212B1 (en) * | 1999-03-18 | 2003-02-18 | United Therapeutics Corporation | Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation |
| CA2367002A1 (en) * | 1999-03-19 | 2000-09-28 | Michael A. Moskowitz | Increasing cerebral bioavailability of drugs |
| CH693905A5 (de) * | 1999-04-15 | 2004-04-15 | Eprova Ag | Stabile kristalline Salze von 5-Methyltetrahydrofolsäure. |
| GB2355191A (en) * | 1999-10-12 | 2001-04-18 | Laxdale Ltd | Combination formulations for fatigue, head injury and strokes |
| US6544994B2 (en) * | 2000-06-07 | 2003-04-08 | Eprov Ag | Pharmaceutical preparation for treating or preventing cardiovascular or neurological disorders by modulating of the activity of nitric oxide synthase |
-
2005
- 2005-12-08 EP EP05853492A patent/EP1819340A2/en not_active Withdrawn
- 2005-12-08 US US11/720,815 patent/US20100130500A1/en not_active Abandoned
- 2005-12-08 CA CA002588994A patent/CA2588994A1/en not_active Abandoned
- 2005-12-08 JP JP2007545655A patent/JP2008523090A/ja not_active Withdrawn
- 2005-12-08 AU AU2005313940A patent/AU2005313940A1/en not_active Abandoned
- 2005-12-08 WO PCT/US2005/044587 patent/WO2006063215A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008523090A5 (enExample) | ||
| ES2438792T3 (es) | Composiciones terapéuticas que comprenden un antagonista específico de receptor endotelina y un inhibidor de PDE5 | |
| AU2018357775B2 (en) | New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD) | |
| AU2006245770A1 (en) | Combination of the PDE4 inhibitor roflumilast and a tetrahydrobiopterin derivative | |
| US20090062301A1 (en) | Pharmaceutical combination composition comprising at least one pkc inhibitor and at least one ja k3 kinase inhibitor for treating autoimmune disorders | |
| Alvarado et al. | Late-onset pulmonary fibrosis and chest deformity in two children treated with cyclophosphamide | |
| JP2017510624A5 (enExample) | ||
| JP2017200940A (ja) | 肺病態に対する医薬組成物 | |
| ZA200707930B (en) | Roflumilast for the treatment of pulmonary hypertension | |
| PT2827860T (pt) | Utilização de um derivado de pirazole no tratamento de exacerbações agudas da doença pulmonar obstructiva crónica | |
| AU2005313940A1 (en) | Methods and compositions for the treatment of pulmonary hypertension of the newborn | |
| TWI606826B (zh) | 艾拉莫德或其鹽之用途 | |
| WO2016066851A1 (en) | Combination for the treatment of conditions involving muscular pain | |
| JPWO2019232130A5 (enExample) | ||
| CN102271689A (zh) | 氦-氧气体混合物用于治疗肺动脉高压的用途 | |
| WO2012097750A1 (zh) | 用于治疗阳痿的吡唑并嘧啶酮化合物和咪唑并三嗪酮化合物 | |
| JP2009510142A (ja) | 急性および慢性肺障害の処置のための可溶性グアニル酸シクラーゼ活性化剤の使用 | |
| ZA200602536B (en) | Use of BH4 for the treatment of respiratory diseases | |
| JP2010163426A (ja) | ホスホジエステラーゼ５阻害剤とアルギニンを含有する医薬組成物 | |
| JP2012509869A (ja) | うつ病、不安、統合失調症、睡眠障害、及びてんかん治療のためのコハク酸のコリン塩 | |
| JP6188784B2 (ja) | 炎症性および免疫性疾患の治療のための組成物 | |
| JP2004051639A (ja) | 動脈硬化症治療のための医薬組成物 | |
| JPS634806B2 (enExample) | ||
| US20240024329A1 (en) | COMBINATION DRUG PRODUCTS FOR TREATING PATIENTS SUFFERING FROM ONE OR MORE MEDICAL CONDITIONS CAUSED BY CORONAVIRUS INFECTION, INCLUDING BY SARS-CoV-2, ITS ALPHA, BETA, DELTA, OR OMICRON VARIANTS AND SUB VARIANTS | |
| CN120899911A (zh) | JAK抑制剂或Janus激酶蛋白降解剂治疗纤维化的用途和方法 |